Zucara Therapeutics Receives Cash Injection to Advance Novel Diabetes Drug Therapy to Prevent Hypoglycemia

Ontario Industry Updates
Written By Guest User

Vancouver and Toronto, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI).

Read the full press release on Zucara's website

Guest User
Previous

CAAP Company: BrainFx's The Living Brain Bank™
Next

Synaptive Medical and General Atlantic Announce Strategic Partnership